Home
News & Events
News
117
Results found
-
Article published in Drug Discovery Today: Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?
"A more high-level definition would be preferred while allowing further specification". -
2024 RSNN Annual Workshop Report available now
The full report of the RSNN Annual Workshop titled "Artificial Intelligence in Regulatory Innovation”, which took place on 11 June 2024 is now available. -
Presentations from RSNN FIGON session now available
On 16 October RSNN organized a parallel session at the FIGON Dutch Medicines Days on the topic "Zooming in on the Pharmaceutical Legislation - Unmet Medical Need". The slides presented during this session are now available for download. -
RSNN Expert Meeting Report – Companion Diagnostics – Challenges and Opportunities
On 28 May 2024, RSNN organised an expert meeting with the title ‘Companion Diagnostics – Challenges and Opportunities’. The goal of this RSNN Expert Meeting was to retrieve information from the field in terms of developments, missed topics or technologies, challenges and opportunities related to CDx. -
RSNN Expert Meeting Report: Addressing the framework of unmet medical need
The RSNN Expert Meeting "Addressing the framework of unmet medical need" took place on Tuesday 23 April 2024. -
RSNN SIG ATMPs and FAST workshop and networking event: presentation file and photos now available
On Tuesday 11 June, the RSNN SIG Advanced Therapies together with the Centre for Future Affordable Sustainable Therapy development (FAST) organised a workshop & networking event. -
RSNN workshop 2024: presentation files and photos now available
On 11 June the RSNN organized its Annual Workshop. We are looking back at a successful Regulatory Science Network Netherlands (RSNN) Annual workshop last Tuesday on the topic of Artificial Intelligence in Regulatory Innovation. -
Article published in Clinical Pharmacology & Therapeutics on the evolution and future of Regulatory Sciences in the Netherlands
Regulatory sciences make medicines work! This is the conclusion of the recently published article in Clinical Pharmacology & Therapeutics (published online ahead of print). In the article, the Netherlands emerges as a vibrant hub for drug regulatory science, blending national expertise with international collaboration. -
Eindrapportage deelopdrachten van het deelprogramma Regulatoire Pandemische Paraatheid gepubliceerd
Na de eerdere presentatie van de voorlopige resultaten van het ZonMw deelprogramma Regulatoire Pandemische Paraatheid op het Ministerie van VWS in november en -
Register now for the RSNN Annual Workshop 2024: Artificial intelligence in Regulatory Innovation
Registration for the RSNN Annual Workshop 2024: "Artificial Intelligence in Regulatory Innovation" is now open. The event will take place in person at Villa Jongerius in Utrecht. Please visit the event site for registration. -
Deelprogramma Regulatoire Pandemische Paraatheid: eindrapport onderzoeksthema Drug Repurposing nu beschikbaar
Na de eerdere presentatie van de voorlopige resultaten van het ZonMw deelprogramma Regulatoire Pandemische Paraatheid op het Ministerie van VWS in November en de publicatie van de -
Terugblik op de geslaagde RSNN lunch webinar "Klinisch Onderzoeksklimaat in Nederland"
Op 8 februari 2024 organiseerde het RSNN in samenwerking met Dutch Clinical Research Foundation (DCRF) en andere stakeholders een lunch webinar met meer dan 160 deelnemers. -
RSNN Expert Meeting Report: Dutch Clinical Trial Landscape
On 25 October 2023 the RSNN Expert Meeting “Dutch Clinical Trial Landscape” took place. The full report (in Dutch) of the meeting is available now: pdf link. -
RSNN Newsletter December 2023
A new edition of the RSNN Newsletter has just been published. -
RSNN interview series: Thera Max-Mos
The RSNN interview series aims to give a better insight into the persons and organizations involved in the activities of RSNN. The series also provide an opportunity to highlight some of the current topics in the Regulatory Science field.